Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium (REVEAL)

AstraZeneca

Status: Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: 2L Treatment; Drug: 1L treatment; Drug: 3L treatment

Study type: Observational

Funder types: Industry

Identifiers

NCT03761901

D5161R00007

Details and patient eligibility

About

This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium

Enrollment: 141 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, aged at least 18 years
• Pathologically confirmed NSCLC
• Tumour harbours a mutation of EGFR
• Diagnosis (radiologically or pathologically confirmed) of locally advanced or metastatic NSCLC, not amenable to curative surgery or chemoradiotherapy between 01 September 2015 and 31 December 2017

Exclusion criteria

• No follow-up data available after diagnosis of locally advanced or metastatic EGFRm NSCLC
• Patients who objected to participation to the study

Trial design

141 participants in 1 patient group

Patients with EGFR mutation positive NSCLC

Treatment:

Drug: 2L Treatment

Drug: 1L treatment

Drug: 3L treatment